FDA Approves First Pancreatic Cancer Drug Targeting RAS

A new drug nearly doubles survival time for people with metastatic pancreatic cancer by targeting a gene mutation scientists once thought was impossible to block.

The breakthrough offers hope for one of the deadliest cancers.